An AI-driven app called juli improved symptoms of asthma and depression, two randomized controlled trials found. The app takes in data from electronic medical records, smartphones, wearable devices, the environment and patient questionnaires to provide personalized health recommendations.
Just 10% of women who had post-miscarriage depression during the pandemic received the “full spectrum of treatment” through therapy and antidepressants, according to a new report by Evernorth Research Institute.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Less than 20% of behavioral healthcare providers collect data on how patients are progressing with their treatment. To buck this trend, Two Chairs is rolling out “mental health snapshots,” which are consistent summaries of patients’ well-being designed to offer real-time insight to both clinicians and clients.
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
A Relmada Therapeutics drug candidate for major depressive disorder failed a Phase 3 clinical trial, but the biotech isn’t giving up on its pill yet. It’s pinning its hopes on additional studies testing the therapy as an additional treatment alongside other depression drugs.
In order to make an impact and improve physical and mental health, we need to recognize the need to approach loneliness as a condition. Building connections through social intervention is the most direct way to affect change.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
The FDA has approved Axsome Therapeutics drug Auvelity as a treatment for major depressive disorder in adults. The regulatory decision makes the twice-daily pill the first new oral drug approved to address a novel depression target in more than 60 years.
Clinicians used to wonder if there was a role for mindfulness meditation in healthcare. But after the Covid-19 pandemic laid bare the overwhelming need for practical solutions in behavioral health, the question has shifted to what role it can play.
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target but the biotech notes that its research has shown the potential to bring psychedelic drugs beyond psychiatry.
Centers for Medicare & Medicaid Services only recently gave the green light for Medicare Advantage (MA) plans to provide a wider range of benefits that address social determinants of health. With that new charge, it’s time for health care payers to join the fight against loneliness.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
A study published by Verily researchers showed that some smartphone metrics, such as sentiment in weekly voice diaries, matched up with the severity of users’ depression as determined by PHQ-9 scores. Even if these technologies could be used to track mental health, it’s not clear how they will fit into physician workflows or how comfortable people will be using their smartphones in this way.
The company recently finished a study showing patients in the U.K. who used both Sleepio’s app and therapy saw improvements in anxiety and depression compared to people who used therapy alone. But the study also had several limitations.
Happify is making its app-based treatment available to patients thanks to a loosened FDA guidance last year that lets digital health companies targeting some behavioral health conditions release their product without clearance. The company is launching an investigational study to get data for a future FDA submission.
A Sage Therapeutics depression drug that failed a pivotal study in 2019 has positive preliminary results from a new Phase 3 clinical trial, but the data also showed the therapy's effects waned over time. Questions about zuranolone’s durability are relevant to Biogen, which committed $1.5 billion to Sage in large part due to the drug’s potential in multiple psychiatric indications.
Healthcare staff are working through immense loss, grief and uncertainty to provide care during the Covid-19 pandemic. As organizations think about how to support their staff, speakers at a MedCity INVEST panel said they must first talk about it openly and provide a safe space for workers to discuss their feelings.